StreetInsider.com News Articles

Form SCHEDULE 13D Dermata Therapeutics, Filed by: Van Hoose Kyri K.

Mon, 01 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260601/26584400.html

Form SCHEDULE 13D Dermata Therapeutics, Filed by: Van Hoose Kyri K.

Mon, 01 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260601/26584400.html

Form EFFECT Dermata Therapeutics,

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578476.html

Form EFFECT Dermata Therapeutics,

Mon, 01 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260601/26578476.html

Form 424B3 Dermata Therapeutics,

Fri, 29 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260529/26576682.html

Form 424B3 Dermata Therapeutics,

Fri, 29 May 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260529/26576682.html

Form 8-K Dermata Therapeutics, For: May 27

Wed, 27 May 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260527/26558838.html

Form 8-K Dermata Therapeutics, For: May 27

Wed, 27 May 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260527/26558838.html

Dermata Therapeutics, Inc (DRMA) files $100M mixed shelf

Fri, 22 May 2026 17:18:59 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) has filed $100,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Subscription Rights

Units

Dermata Therapeutics, Inc (DRMA) files $100M mixed shelf

Fri, 22 May 2026 17:18:59 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) has filed $100,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Subscription Rights

Units

Form S-3/A Dermata Therapeutics,

Fri, 22 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260522/26542859.html

Form S-3/A Dermata Therapeutics,

Fri, 22 May 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260522/26542859.html

Dermata Therapeutics, Inc (DRMA) Misses Q1 EPS by 48c

Wed, 13 May 2026 17:20:52 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q1 EPS of ($0.48).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.

Form SCHEDULE 13G/A Dermata Therapeutics, Filed by: INTRACOASTAL CAPITAL, LLC

Wed, 13 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260513/26486973.html

Form SCHEDULE 13G/A Dermata Therapeutics, Filed by: INTRACOASTAL CAPITAL, LLC

Wed, 13 May 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260513/26486973.html

Form 10-Q Dermata Therapeutics, For: Mar 31

Wed, 13 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260513/26485995.html

Form 10-Q Dermata Therapeutics, For: Mar 31

Wed, 13 May 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260513/26485995.html

Form 8-K Dermata Therapeutics, For: Mar 31

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485894.html

Form 8-K Dermata Therapeutics, For: Mar 31

Wed, 13 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260513/26485894.html

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

Wed, 13 May 2026 16:05:00 -0400

- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -

- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 -

- Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility -

SAN DIEGO, CA / ACCESS Newswire / May 13, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA, DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026

Wed, 13 May 2026 16:05:00 -0400

- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products -

- Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to support skin renewal, in the middle of 2026 -

- Raised $2.0 million in net proceeds from it's at-the-market ("ATM") financing facility -

RBC Capital Starts Dermata Therapeutics In (DRMA) at Outperform

Thu, 23 Apr 2026 16:13:54 -0400

RBC Capital analyst Brian Abrahams initiates coverage on Dermata Therapeutics In (NASDAQ: DRMA) with a Outperform rating and a price target of $40.00.

The analyst comments "We like DMRA's approach, capitalizing on an increasingly validated approach of using mCALR antibodies in myeloproliferative neoplasms (MPNs) - helping de-risk despite its early stage - and with key improvements over INCY's mid-stage candidate '989 that should enable a more impressive clinical profile and market opportunity. As lead drug '001 and the rest of DMRA's portfolio advances, and INCY's data continue to generate comfort around the mechanism and regulatory path, we expect DMRA shares to

RBC Capital Starts Dermata Therapeutics In (DRMA) at Outperform

Thu, 23 Apr 2026 16:13:54 -0400

RBC Capital analyst Brian Abrahams initiates coverage on Dermata Therapeutics In (NASDAQ: DRMA) with a Outperform rating and a price target of $40.00.

Form SCHEDULE 13G/A Dermata Therapeutics, Filed by: BIGGER CAPITAL FUND L P

Wed, 22 Apr 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260422/26351754.html

Form SCHEDULE 13G/A Dermata Therapeutics, Filed by: BIGGER CAPITAL FUND L P

Wed, 22 Apr 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260422/26351754.html